DERMIRA, INC.ELI LILLY & Co • January 22nd, 2020 • Pharmaceutical preparations
Bald Eagle Acquisition Corporation, a Delaware corporation (“Purchaser”) and wholly-owned subsidiary of Eli Lilly and Company, an Indiana corporation (“Lilly”), is offering to purchase all of the outstanding shares of common stock, par value, $0.001 per share (the “Shares”), of Dermira, Inc., a Delaware corporation (“Dermira”), at a purchase price of $18.75 per Share (the “Offer Price”), net to the seller in cash, without interest and less any applicable tax withholding, upon the terms and subject to the conditions set forth in this Offer to Purchase and in the related Letter of Transmittal (which, together with this Offer to Purchase, as they may be amended or supplemented from time to time, collectively constitute the “Offer”).
AMENDMENT NO. 2 TO MUTUAL NON-DISCLOSURE AGREEMENTNon-Disclosure Agreement • January 22nd, 2020 • ELI LILLY & Co • Pharmaceutical preparations
THIS AMENDMENT NO. 2 TO MUTUAL NON-DISCLOSURE AGREEMENT NUMBER ONE (the “Amendment”) is made as of January 3, 2020 (“Amendment Effective Date”) by and between Dermira, Inc., a Delaware corporation (including its subsidiaries), whose address is 275 Middlefield Road, Suite 150, Menlo Park, CA 94025, USA (“Dermira”), and Eli Lilly and Company, an Indiana corporation, whose address is Lilly Corporate Center, Indianapolis, Indiana 46285 (“Company”).
AMENDMENT NO. 1 TO MUTUAL NON-DISCLOSURE AGREEMENTNon-Disclosure Agreement • January 22nd, 2020 • ELI LILLY & Co • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO MUTUAL NON-DISCLOSURE AGREEMENT NUMBER ONE (the “Amendment”) is made as of November 11, 2019 (“Amendment Effective Date”) by and between Dermira, Inc., a Delaware corporation (including its subsidiaries), whose address is 275 Middlefield Road, Suite 150, Menlo Park, CA 94025, USA (“Dermira”), and Eli Lilly and Company, an Indiana corporation, whose address is Lilly Corporate Center, Indianapolis, Indiana 46285 (“Company”).
MUTUAL NON-DISCLOSURE AGREEMENTMutual Non-Disclosure Agreement • January 22nd, 2020 • ELI LILLY & Co • Pharmaceutical preparations • New York
This Mutual Non-Disclosure Agreement (this “Agreement”) is entered into on the last date signed below (“Effective Date”), between Dermira, Inc., a Delaware corporation (including its subsidiaries), whose address is 275 Middlefield Road, Suite 150, Menlo Park, CA 94025, USA (“Dermira”), and Eli Lilly and Company, an Indiana corporation, whose address is Lilly Corporate Center, Indianapolis, Indiana 46285 (“Company”).
